发布求助
文献互助 智能选刊 最新文献

European Cardiology Review最新文献

筛选
英文 中文
Comment on the ESC Guidelines 2022 for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. 对2022年ESC室性心律失常患者管理和预防心源性猝死指南的评论
IF 3
European Cardiology Review Pub Date : 2023-02-01 DOI: 10.15420/ecr.2022.48
David Calvo Cuervo
{"title":"Comment on the ESC Guidelines 2022 for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death.","authors":"David Calvo Cuervo","doi":"10.15420/ecr.2022.48","DOIUrl":"https://doi.org/10.15420/ecr.2022.48","url":null,"abstract":"<p><p>The European Society of Cardiology guidelines for the management of sudden cardiac death and ventricular arrhythmias have been updated. Additions and amendments range from clinical management to invasive procedures, and provide new perspectives on integrated management, genetic testing, stratification of risk, arrhythmia ablation and device therapy among others. Significant improvements have been made, which will result in better care for patients and families.</p>","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/59/7d/ecr-18-e01.PMC9947934.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9781221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dyspnea in Oncological Patients: a Brain Teaser. 肿瘤患者的呼吸困难:一个脑筋急转弯。
IF 3
European Cardiology Review Pub Date : 2023-02-01 DOI: 10.15420/ecr.2021.62
Kalliopi Keramida, Athanasios Kostoulas
{"title":"Dyspnea in Oncological Patients: a Brain Teaser.","authors":"Kalliopi Keramida,&nbsp;Athanasios Kostoulas","doi":"10.15420/ecr.2021.62","DOIUrl":"https://doi.org/10.15420/ecr.2021.62","url":null,"abstract":"<p><p>Dyspnea is one of the most common symptoms in oncological patients with greater prevalence in lung cancer and advanced disease states. Causes of dyspnea can be directly or indirectly associated with cancer, anti-neoplastic therapies and comorbidities unrelated to cancer. Routine screening of dyspnea is suggested for all oncological patients by using unidimensional, simple scales and multidimensional tools to capture more domains affected by this symptom and to assess the effectiveness of interventions. The first step in the treatment algorithm of dyspnea is the identification of potentially reversible causes; if no specific cause is depicted, symptomatic treatment with non-pharmacological and pharmacological interventions is suggested. Referral to palliative care and continuous palliative sedation are the last resort in patients with a very limited life expectancy of not more than a few days for symptomatic relief and to decrease of the distress of patients and caregivers.</p>","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/cc/f3/ecr-18-e03.PMC9947930.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10850309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Efficacy of Ranolazine to Improve Diastolic Performance in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-analysis. 雷诺嗪改善保留射血分数的心力衰竭患者舒张功能的疗效:一项系统综述和荟萃分析。
IF 3
European Cardiology Review Pub Date : 2023-02-01 DOI: 10.15420/ecr.2022.10
Desak Ketut Sekar Cempaka Putri, Andrianto Andrianto, Makhyan Jibril Al-Farabi, Pandit Bagus Tri Saputra, Ricardo Adrian Nugraha
{"title":"Efficacy of Ranolazine to Improve Diastolic Performance in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-analysis.","authors":"Desak Ketut Sekar Cempaka Putri,&nbsp;Andrianto Andrianto,&nbsp;Makhyan Jibril Al-Farabi,&nbsp;Pandit Bagus Tri Saputra,&nbsp;Ricardo Adrian Nugraha","doi":"10.15420/ecr.2022.10","DOIUrl":"https://doi.org/10.15420/ecr.2022.10","url":null,"abstract":"<p><p>This article evaluates the efficacy of using ranolazine to improve diastolic performance and exercise capacity in heart failure with preserved ejection fraction. A comprehensive literature review found eight trials where there are no significant difference in peak O2 (p=0.09) and exercise duration (p=0.18) between ranolazine and placebo. The ranolazine group had significantly higher and better diastolic parameters compared to placebo, with a mean difference of 0.45 (95% CI [27.18-39.50]). There were no significant differences for haemodynamic parameters (blood pressure and heart rate) and electrocardiography (QT interval) between ranolazine and placebo. The review found that ranolazine has good wefficacy to improve diastolic performance among heart failure with preserved ejection fraction patients and it does not affect blood pressure, heart rate and rate of ventricular repolarisation (shortening of the QT interval).</p>","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a8/d9/ecr-18-e02.PMC9947928.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10850308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Perspectives and Future Directions of Anticoagulant Therapy in Coronary Artery Disease Patients. 冠心病患者抗凝治疗的展望与未来方向。
IF 3
European Cardiology Review Pub Date : 2023-01-01 DOI: 10.15420/ecr.2022.66
Maki Komiyama, Gheorghe-Andrei Dan, Koji Hasegawa
{"title":"Perspectives and Future Directions of Anticoagulant Therapy in Coronary Artery Disease Patients.","authors":"Maki Komiyama,&nbsp;Gheorghe-Andrei Dan,&nbsp;Koji Hasegawa","doi":"10.15420/ecr.2022.66","DOIUrl":"https://doi.org/10.15420/ecr.2022.66","url":null,"abstract":"<p><p>Antiplatelet agents are routinely used to treat patients with chronic atherosclerotic coronary artery disease. Treatment with the addition of a low dose of rivaroxaban as dual-pathway inhibition (DPI) decreases ischaemic events at the expense of increased bleeding. At present, the balance between thrombotic and bleeding risks must be carefully weighed up when considering DPI. However, with the introduction of activated coagulation factor XI inhibitors, which have fewer bleeding effects, the use of DPI in patients with atherosclerotic cardiovascular diseases could be extended.</p>","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0d/94/ecr-18-e14.PMC10316355.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9793294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition: The Big Step Forward in Lipid Control. 蛋白转化酶枯草杆菌素/可欣9型抑制:脂质控制的一大进步。
IF 3
European Cardiology Review Pub Date : 2023-01-01 DOI: 10.15420/ecr.2023.14
Rishi Rikhi, Michael D Shapiro
{"title":"Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition: The Big Step Forward in Lipid Control.","authors":"Rishi Rikhi,&nbsp;Michael D Shapiro","doi":"10.15420/ecr.2023.14","DOIUrl":"https://doi.org/10.15420/ecr.2023.14","url":null,"abstract":"<p><p>The breakthrough discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9) 20 years ago revolutionised the current understanding of cholesterol homeostasis. Genetic studies have shown that gain-of-function mutations in <i>PCSK9</i> lead to elevated LDL cholesterol and increased risk of atherosclerotic cardiovascular disease, while loss-of-function mutations in <i>PCSK9</i> result in lifelong low levels of circulating LDL cholesterol and dramatic reduction in atherosclerotic cardiovascular disease. Therapies inhibiting PCSK9 lead to a higher density of LDL receptor on the surface of hepatocytes, resulting in greater ability to clear circulating LDL. Thus far, randomised controlled trials have shown that subcutaneous fully human monoclonal antibodies targeting PCSK9, evolocumab and alirocumab, and <i>PCSK9</i> silencing with inclisiran result in drastic reductions in LDL cholesterol. Additionally, several novel strategies to target PCSK9 are in development, including oral antibody, gene silencing, DNA base editing and vaccine therapies. This review highlights the efficacy, safety and clinical use of these various approaches in PCSK9 inhibition.</p>","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c8/a6/ecr-18-e45.PMC10345936.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9880458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Cancer and Postradiotherapy Cardiotoxicity: How to Face Damage in Women's Hearts? 癌症和放疗后心脏毒性:如何面对女性心脏损伤?
IF 3
European Cardiology Review Pub Date : 2023-01-01 DOI: 10.15420/ecr.2022.36
Amalia Peix, Aylen Perez, Ana Maria Barreda
{"title":"Cancer and Postradiotherapy Cardiotoxicity: How to Face Damage in Women's Hearts?","authors":"Amalia Peix,&nbsp;Aylen Perez,&nbsp;Ana Maria Barreda","doi":"10.15420/ecr.2022.36","DOIUrl":"https://doi.org/10.15420/ecr.2022.36","url":null,"abstract":"<p><p>Cancer and cardiovascular disease are the two main causes of death worldwide in both men and women. In the past decades, survival rate in cancer patients has substantially improved due to new treatments and developments in radiation therapy (RT). In women, breast cancer (BC) is the leading cause of cancer death and thoracic RT is a main component of the treatment in many cases. Nevertheless, despite new techniques that limit the area receiving RT, cardiac damage is still an important concern in BC patients. In this review, the following aspects will be addressed: pathophysiology of postradiotherapy heart damage in women with BC; mechanisms, diagnosis and prevention/management of heart damage; and future areas of potential research for radiotherapy injury in women.</p>","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/54/bf/ecr-18-e08.PMC10291578.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9723911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nuclear Factor-κB is a Prime Candidate for the Diagnosis and Control of Inflammatory Cardiovascular Disease. 核因子-κB是诊断和控制炎症性心血管疾病的主要候选者。
IF 3
European Cardiology Review Pub Date : 2023-01-01 DOI: 10.15420/ecr.2023.10
Akira Matsumori
{"title":"Nuclear Factor-κB is a Prime Candidate for the Diagnosis and Control of Inflammatory Cardiovascular Disease.","authors":"Akira Matsumori","doi":"10.15420/ecr.2023.10","DOIUrl":"https://doi.org/10.15420/ecr.2023.10","url":null,"abstract":"<p><p>Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) is responsible for the regulation of genes involved in inflammation and immune responses. NF-κB may play an important role in cardiovascular diseases (CVDs), atherosclerosis and diabetes. Several therapeutic agents used for the treatment of CVDs and diabetes, such as pimobendan and sodium-glucose cotransporter 2 inhibitors, exert anti-inflammatory effects by inhibiting NF-κB activation; anti-inflammatory therapy may have beneficial effects in CVDs and diabetes. Several pharmacological agents and natural compounds may inhibit NF-κB, and these agents alone or in combination may be used to treat various inflammatory diseases. Immunoglobulin-free light chains could be surrogate biomarkers of NF-κB activation and may be useful for evaluating the efficacy of these agents. This review discusses recent advances in our understanding of how the NF-κB signalling pathway controls inflammation, metabolism and immunity, and how improved knowledge of these pathways may lead to better diagnostics and therapeutics for various human diseases.</p>","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fb/a6/ecr-18-e40.PMC10345985.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9880457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Oral Presentation Award Winner: The Predictive Value of NT-proBNP across Glomerular Filtration Rate Subsets in Heart Failure Treated Patients. 口头报告奖得主:NT-proBNP对心力衰竭患者肾小球滤过率亚群的预测价值。
IF 3
European Cardiology Review Pub Date : 2023-01-01 DOI: 10.15420/ecr.2023.18.PO1
Diana Ionescu, Caterina Delcea, Cătălin Adrian Buzea, Ancuta Vîjan, Ruxandra Martin, Elisabeta Bădilă, Gheorghe-Andrei Dan
{"title":"Oral Presentation Award Winner: The Predictive Value of NT-proBNP across Glomerular Filtration Rate Subsets in Heart Failure Treated Patients.","authors":"Diana Ionescu,&nbsp;Caterina Delcea,&nbsp;Cătălin Adrian Buzea,&nbsp;Ancuta Vîjan,&nbsp;Ruxandra Martin,&nbsp;Elisabeta Bădilă,&nbsp;Gheorghe-Andrei Dan","doi":"10.15420/ecr.2023.18.PO1","DOIUrl":"https://doi.org/10.15420/ecr.2023.18.PO1","url":null,"abstract":"","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/35/94/ecr-18-e18.PMC10316358.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9802290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Importance of Oxidative Stress Biomarkers and the Need of Antioxidant Therapy in the Control of Cardiac Arrhythmias. 氧化应激生物标志物的重要性及抗氧化治疗在心律失常控制中的必要性。
IF 3
European Cardiology Review Pub Date : 2023-01-01 DOI: 10.15420/ecr.2023.18.PO15
Maria Cristina Bezna, Suzana Danoiu, Marinela Bezna, Iulia-Andreea Voisneanu, Amelia Genunche-Dumitrescu, Octavian Istratoaie
{"title":"The Importance of Oxidative Stress Biomarkers and the Need of Antioxidant Therapy in the Control of Cardiac Arrhythmias.","authors":"Maria Cristina Bezna,&nbsp;Suzana Danoiu,&nbsp;Marinela Bezna,&nbsp;Iulia-Andreea Voisneanu,&nbsp;Amelia Genunche-Dumitrescu,&nbsp;Octavian Istratoaie","doi":"10.15420/ecr.2023.18.PO15","DOIUrl":"https://doi.org/10.15420/ecr.2023.18.PO15","url":null,"abstract":"","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a7/d4/ecr-18-e32.PMC10316352.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9802287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension: Clinical Outcomes. 球囊肺血管成形术治疗慢性血栓栓塞性肺动脉高压:临床结果。
IF 3
European Cardiology Review Pub Date : 2023-01-01 DOI: 10.15420/ecr.2022.29
Irene M Lang
{"title":"Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension: Clinical Outcomes.","authors":"Irene M Lang","doi":"10.15420/ecr.2022.29","DOIUrl":"https://doi.org/10.15420/ecr.2022.29","url":null,"abstract":"<p><p>Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare major vessel pulmonary vascular disease that is characterised by fibrotic obstructions deriving from an organised clot. Recent advances in treatments for CTEPH have significantly improved outcomes. Apart from classical surgical pulmonary endarterectomy, balloon pulmonary angioplasty (BPA) and vasodilator drugs that were tested in randomised controlled trials of non-operable patients are now available. In Europe, CTEPH affects males and females equally. In the first European CTEPH Registry, women with CTEPH underwent pulmonary endarterectomy less frequently than men, especially at low-volume centres. In Japan, CTEPH is more common in females and is predominantly treated by BPA. More data on gender-specific outcomes are expected from the results of the International BPA Registry (NCT03245268).</p>","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2e/0f/ecr-18-e11.PMC10316354.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9802288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信